Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 04/20 04:59:36 pm
284.2 DKK   -1.17%
04/21NOVO NORDISK A/ : You show 'em Marco!
04/19NOVO NORDISK A/ : - Share repurchase programme
04/19NOVO NORDISK A/ : Boys & Girls Clubs of Mercer County’s Garden..
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
04/21NOVO NORDISK A/S : commits nearly $7 million for Minglin Ma`s diabetes research
04/21NOVO NORDISK A/S : and Red Cross to tackle NCDs in humanitarian crises
04/21NOVO NORDISK A/S : Sempre Health and Novo Nordisk to partner to lower diabetes d..
04/21NOVO NORDISK A/S : You show 'em Marco!
04/19NOVO NORDISK A/S : New Findings Reported from Novo Nordisk Describe Advances in ..
04/19NOVO NORDISK A/S : Studies from Novo Nordisk Add New Findings in the Area of Typ..
04/19NOVO NORDISK A/S : Red Cross, Novo Nordisk Announce Ground-Breaking Partnership ..
04/19NOVO NORDISK A/S : - Share repurchase programme
04/19NOVO NORDISK A/S : Boys & Girls Clubs of Mercer County’s Garden, Outdoor E..
04/18NOVO NORDISK A/S : Xultophy® approved in Canada for the treatment of adults with..
More news
News from SeekingAlpha
04/19Novartis Q1 results weigh on pharma stocks 
04/17A Look At The Junior Cobalt Miners In Early 2018 
04/14VENTURE CAPITAL DEALS OF THE WEEK : Tencent Led $3B Investment 
04/04Nick's Portfolio Review Q1 2018 
04/03CMS finalizes policies to reduce drug costs for Medicare beneficiaries 
Financials ( DKK)
Sales 2018 110 B
EBIT 2018 46 523 M
Net income 2018 38 732 M
Finance 2018 16 988 M
Yield 2018 2,82%
P/E ratio 2018 17,76
P/E ratio 2019 17,64
EV / Sales 2018 4,93x
EV / Sales 2019 4,63x
Capitalization 558 B
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 330  DKK
Spread / Average Target 16%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-15.04%92 039
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890